Hims & Hers Health Inc. (HIMS) 今日盘中股价大幅上涨9.74%，引起了市场的广泛关注。
消息面上，美国食品药品监督管理局(FDA)正计划对肽类药物监管进行松绑。根据相关文件，FDA将于7月召集专家小组，讨论部分药店生产某些肽类物质的可行性，并敲定松绑细节。据悉，FDA正在考虑将12种肽类药物从二级限制清单中移除，另有7种肽类药物将于7月接受审查。
肽类药物被广泛应用于复方制剂领域，近年来受到严格监管。Hims & Hers Health作为一家平价减肥药及健康服务供应商，其减重与健康业务有望直接受益于此次监管放松。市场预期，监管环境的改善将有利于公司相关产品的市场拓展与业务增长，从而推动了投资者情绪的升温和股价的走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.